Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

iomedicine.com/leadership#Warmuth">Markus Warmuth, M.D., President and Chief Executive Officer, H3 Biomedicine. "Both H3 Biomedicine and Selvita value early validation of drug targets to achieve preclinical proof of concept followed by translation of these findings into novel therapies for targeted patient populations. This collaboration is a key tool in our arsenal as it brings Selvita's kinase biology platform and medicinal chemistry capabilities together with H3's expertise in target validation, bioinformatics and genomics analysis. We look forward to working with Selvita to ultimately bring efficacious medicines to patients."

Pawel Przewiezlikowski, Chief Executive Officer of Selvita, said, "We are delighted to enter into this collaboration with H3 Biomedicine, and to apply our kinase discovery platform to jointly advance target discovery. The unique target identification and validation competences of H3 will bring our discovery efforts to a new level."

Krzysztof Brzozka, Chief Scientific Officer of Selvita, added "Both H3 and Selvita teams have always strived to identify novel therapeutic solutions for people living with cancer and we are very pleased that we can now join forces. This collaboration will enable us to significantly increase the breadth and depth of our pipeline."

About H3 Biomedicine Inc.
H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit http://www.h3biomedicine.com/ for more information.

About Selvita
Selvita is a Polish biotechnology company engaged in the discovery and developme
'/>"/>

SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Seventh Wave Laboratories, a consulting-based ... of pharmaceutical products and medical devices, announced the purchase ... a 50,000 sq. ft. building more than three times ... growth. Facility renovations will begin immediately and the gradual ... occur in September. , “We are excited about ...
(Date:5/21/2015)... 21, 2015 uBiome, the leading ... partnership with PicnicHealth, a healthcare company that collects ... with Inflammatory Bowel Disease (IBD) will receive a ... uBiome research kit. Both companies were funded by ... , For more information on this partnership and ...
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains to an ... within a body lumen (open space). Known as ... cost, single-use disposable illumination and camera module (housing). ... and the patent approval was received on January 6, ... the lighting and magnification of the endoscope for different ...
(Date:5/21/2015)... VANCOUVER , May 21, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... an upcoming poster presentation at the International Society ... treatment for chronic Achilles tendinosis currently in a ... on May 29 th from 5:30 PM ...
Breaking Biology Technology:Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... March 3, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... by developing novel medicines for the treatment of hepatitis C, ... fourth quarter and year ended December 31, 2010. ... create value in the evolving HCV landscape," said Steve Worland, ...
... Life Sciences, Inc. (Nasdaq: CALP ) today ... its Wako Diagnostics division, has obtained 510(k) clearance from ... uTASWako ® i30 Immunoanalyzer and AFP-L3 and DCP ... in patients with chronic liver disease.  The i30 Immunoanalyzer, ...
... of Pennsylvania demonstrates a more consistent and cost-effective method ... applications in a variety of fields, and was the ... As explained in a recently published study, a Penn ... is just a single atom thick over 95% of ...
Cached Biology Technology:Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights 7Caliper's Microfluidic Technologies Enable 510(k) Approved Multiplexed Immunoassay System for Liver Cancer Risk Assessment 2Penn physicists develop scalable method for making graphene 2Penn physicists develop scalable method for making graphene 3
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... genetic testing methods helped public health officials control and ... hepatitis A virus in 2003 related to the consumption ... in the October 15 issue of The Journal of ... the study, Joseph J. Amon, PhD, MSPH, and colleagues ...
... a mathematical model of the mechanism birds use to ... feather structures involve the coordination of at least two ... "Understanding these mechanisms of feather growth gives a whole ... Richard Prum, senior author on the study. Prum is ...
... gene that controls the speed at which patients develop ... for this disease. The new study published in the ... week provides a new view of the mechanisms underlying ... health efforts aimed at containing the disease. , "About ...
Cached Biology News:Disrupting Cocaine-memories To Battle Addiction 2Simple explanation for complex pattern of feather development 2Scientists discover gene that controls speed of tuberculosis development 2
... The ImmEdge Pen, a hydrophobic barrier ... is designed for use with frozen or ... The ImmEdge Pen provides a heat-stable, water-repellent ... the tissue sections, prevents mixing of reagents ...
...
...
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
Biology Products: